FDA expected to decide on AstraZeneca’s self-administered flu vaccine next quarter

If all goes well at the FDA, As­traZeneca hopes to roll out the US’ first self-ad­min­is­tered flu vac­cine ahead of the next cold and flu sea­son, the com­pa­ny an­nounced on Tues­day.

As­traZeneca’s Flu­Mist Quadri­va­lent nasal spray was ap­proved rough­ly two decades ago for ad­min­is­tra­tion by a health­care pro­fes­sion­al. But if reg­u­la­tors OK As­traZeneca’s lat­est ap­pli­ca­tion, el­i­gi­ble peo­ple would be able to re­ceive the vac­cine by mail and ad­min­is­ter it them­selves or to some­one in their care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.